tradingkey.logo
tradingkey.logo
Search

ProMIS Neurosciences Inc

PMN
Add to Watchlist
13.350USD
-0.100-0.74%
Close 07/02, 13:00ETQuotes delayed by 15 min
119.72MMarket Cap
LossP/E TTM

TradingKey Stock Score of ProMIS Neurosciences Inc

Currency: USD Updated: 2026-07-02

Key Insights

ProMIS Neurosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 98 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ProMIS Neurosciences Inc's Score

Industry at a Glance

Industry Ranking
98 / 387
Overall Ranking
214 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

ProMIS Neurosciences Inc Highlights

StrengthsRisks
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -0.72, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.50M shares, increasing 43.86% quarter-over-quarter.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
35.500
Target Price
+163.94%
Upside Space

FAQs

How does TradingKey generate the Stock Score of ProMIS Neurosciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of ProMIS Neurosciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of ProMIS Neurosciences Inc’s performance and outlook.

How do we generate the financial health score of ProMIS Neurosciences Inc?

To generate the financial health score of ProMIS Neurosciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects ProMIS Neurosciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of ProMIS Neurosciences Inc.

How do we generate the company valuation score of ProMIS Neurosciences Inc?

To generate the company valuation score of ProMIS Neurosciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare ProMIS Neurosciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of ProMIS Neurosciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of ProMIS Neurosciences Inc.

How do we generate the earnings forecast score of ProMIS Neurosciences Inc?

To calculate the earnings forecast score of ProMIS Neurosciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on ProMIS Neurosciences Inc’s future.

How do we generate the price momentum score of ProMIS Neurosciences Inc?

When generating the price momentum score for ProMIS Neurosciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of ProMIS Neurosciences Inc’s prices. A higher score indicates a more stable short-term price trend for ProMIS Neurosciences Inc.

How do we generate the institutional confidence score of ProMIS Neurosciences Inc?

To generate the institutional confidence score of ProMIS Neurosciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about ProMIS Neurosciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of ProMIS Neurosciences Inc.

How do we generate the risk management score of ProMIS Neurosciences Inc?

To assess the risk management score of ProMIS Neurosciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of ProMIS Neurosciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of ProMIS Neurosciences Inc.